According to a filing with the S.E.C., Pursuit Vascular, a Maple Grove, MN-based developer of preventive medical devices for catheter-related bloodstream infections, raised $1.6m in funding.
The backers of the debt round were not disclosed.
Led by President & CEO Doug Killion, Pursuit Vascular is developing a family of products based on its patented ClearGuard™ platform technology, which has been shown to be safe and effective for reducing microbial colonization in hemodialysis catheter hubs.
The first product targets infections associated with hemodialysis catheters.
FinSMEs
16/02/2015